|
|
|
|
|
Sessions of Interest for the Upcoming 2021 Cancers Symposium |
|
|
|
|
|
|
Genitourinary Cancers Symposium 2021 Trials in Progress TROPiCS-04
|
|
Petros Grivas, MD, Ph.D.
|
| Petros Grivas discusses the upcoming ASCO GU 2021 meeting that opens on Thursday, February 11, 2021. Dr. Grivas will be presenting a "Trials in Progress" on the study of sacituzumab govitecan (IMMU-132) in metastatic or locally advanced unresectable urothelial cancer (TROPiCS-04). This is a Phase III, global, multicenter, open-label randomized controlled trial in which approximately 600 subjects with metastatic or locally advanced unresectable UC who have progressed after prior therapy with platinum-based regimen and anti-programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy will be randomized to either sacituzumab govitecan arm or Treatment of Physician's Choice (TPC) arm.
|
|
|
|
|
|
|
|
|
|
| Immunotherapy Nivolumab Doubles Disease-Free Survival in a Type of High-Risk Urothelial Carcinoma
|
| Press Release
|
| Treatment with the immunotherapy nivolumab (Opdivo®) following radical surgery with or without cisplatin-based chemotherapy significantly improved disease-free survival in patients with muscle-invasive urothelial carcinoma, according to a study that will be presented at the 2021 ASCO Genitourinary Cancers Symposium, taking place virtually February 11-13.
|
|
|
|
|
|
| Nivolumab in Combination with Cabozantinib Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma in the Phase 3 CheckMate -9ER Trial
|
| Press Release
|
| Results from a new analyses from the pivotal Phase 3 CheckMate -9ER trial, demonstrating clinically meaningful, sustained efficacy benefits as well as quality of life improvements with the combination of nivolumab and cabozantinib compared to sunitinib in the first-line treatment of advanced renal cell carcinoma (RCC) will be featured in the Poster Highlights Session on February 13 at the 2021 ASCO Genitourinary Cancers Symposium. |
|
|
|
|
|
|
|
| Poster Session - Renal Cell Cancer |
|
|
|
|
|
Biomarker-Based Phase II Study of Sapanisertib (TAK-228), an mTORC1/2 Inhibitor in Patients with Refractory Metastatic Renal Cell Carcinoma (mRCC)
Presented By: Bradley McGregor, MD
|
|
|
|
|
Phase II Trial of Lenvatinib (LEN) at Two Starting Doses + Everolimus (EVE) in Patients (pts) with Renal Cell Carcinoma (RCC): Results by Independent Imaging Review (IIR) and Prior Immune Checkpoint Inhibition (ICI)
Presented By: Sumanta Pal, MD
|
|
|
|
|
Nivolumab + Cabozantinib (NIVO+CABO) Versus Sunitinib (SUN) for Advanced Renal Cell Carcinoma (aRCC): Outcomes by Sarcomatoid Histology and Updated Trial Results with Extended Follow-Up of CheckMate 9ER
Presented By: Robert Motzer, MD
|
|
|
|
|
| Poster Session - Urothelial Carcinoma
|
|
|
|
|
|
Avelumab (Ave) First-Line (1L) Maintenance plus Best Supportive Care (BSC) Versus BSC Alone for Advanced Urothelial Carcinoma (UC): JAVELIN Bladder 100 Japanese Subgroup Analysis
Presented By: Norihiko Tsuchiya, MD
|
|
|
|
|
Avelumab (Ave) First-Line (1L) Maintenance plus Best Supportive Care (BSC) Versus BSC Alone for Advanced Urothelial Carcinoma (UC): JAVELIN Bladder 100 Subgroup Analysis Based on Duration and Cycles of 1L Chemotherapy
Presented By: Yohann Loriot, MD, PhD
|
|
|
|
|
Atezolizumab (Atezo) Monotherapy Versus Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (mUC): Clinical Outcomes by PD-L1 Status in Cisplatin (Cis)-Ineligible Pts from the Phase III IMvigor130 Study
Presented By: Matt Galsky, MD
|
|
|
|
|
|
|
| Trials in Progress Poster Session |
|
|
|
|
|
|
|
PDIGREE: An Adaptive Phase III Trial of PD-Inhibitor Nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI Cabozantinib (CABO) in Metastatic Untreated Renal Cell Cancer (Alliance A031704)
Presented By: Tian Zhang, MD
|
|
|
|
|
MK-6482, a Hypoxia-Inducible Factor 2α Inhibitor (HIF-2α), Versus Everolimus in Heavily Pretreated, Immune Checkpoint–inhibitor-Resistant, Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Phase III Study
Presented By: Toni K. Choueiri, MD
|
|
|
|
|
CONTACT-03: Randomized, Open-Label Phase III Study of Atezolizumab plus Cabozantinib Versus Cabozantinib Monotherapy Following Progression On/after Immune Checkpoint Inhibitor (ICI) Treatment in Patients with Advanced/metastatic Renal Cell Carcinoma
Presented By: Sumanta Pal, MD
|
|
|
|
|
|
|
SURE: An Open Label, Sequential-Arm, Phase II Study of Neoadjuvant Sacituzumab Govitecan (SG), and SG plus Pembrolizumab (Pembro) Before Radical Cystectomy, for Patients with Muscle-Invasive Bladder Cancer (MIBC) Who Cannot Receive or Refuse Cisplatin-Based Chemotherapy
Presented By: Andrea Necchi, MD
|
|
|
|
|
A Phase III, Randomized, Open-Label, Multicenter, Global Study of First-Line Durvalumab plus Standard of Care (SoC) Chemotherapy and Durvalumab plus Tremelimumab, and SoC Chemotherapy Versus SoC Chemotherapy Alone in Unresectable Locally Advanced or Metastatic Urothelial Cancer (NILE)
Presented By: Matt D. Galsky, MD
|
|
|
|
|
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Efficacy and Safety of Durvalumab in Combination with Gemcitabine plus Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Muscle-Invasive Bladder Cancer (NIAGARA)
Presented By: Thomas Powles, MBBS, MRCP, MD
|
|
|
|
|
|
|
|
|
|
|
| The von Hippel-Lindau Tumor Suppressor Protein: Rosetta Stone for Kidney Cancer Pathogenesis and Treatment
|
| Presented By: William Kaelin, MD
|
|
|
|
|
|
|
Optimizing Personalized Management of Nonmuscle-Invasive Bladder Cancer
|
Molecular Landscape of Non-Muscle-Invasive Bladder Cancer and Subcellular Risk Factors for Progression
Presented By: Eugene J. Pietzak, MD
Radical Cystectomy for High-Risk Non-Muscle-Invasive Bladder Cancer: Who and Why?
Presented By: Anne K. Schuckman, MD
|
|
|
|
|
|
|
|
|
|
|
|
| Oral Abstract Session: Urothelial Carcinoma; and Adrenal, Penile, Testicular, and Urethral Cancers
|
| Chair: Jeffrey Holzbeierlein, MD, FACS
|
|
|
|
|
Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
Presented By: Thomas Powles, MBBS, MRCP, MD
|
|
|
|
|
EV-201 Cohort 2: Enfortumab Vedotin in Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer Who Received Prior PD-1/PD-L1 Inhibitors.
Presented By: Arjun Balar, MD
|
|
|
|
|
|
|
| Navigating Uncertain Times in Muscle-Invasive and Advanced Bladder Cancer
|
| Chair(s):James M. McKiernan, MD and Andrea B. Apolo, MD
|
|
|
|
|
Role of Definitive Local Therapy After Complete Clinical Response to Neoadjuvant Chemotherapy
Presented By: Chad Ritch, MD, MBA
|
|
|
|
|
First Results from the Phase 3 CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)
Presented By: Dean F. Bajorin, MD
|
|
|
|
|
|
|
| Rapid Abstract Session: Urothelial Carcinoma and Rare Tumors
|
| Chair: Girish S. Kulkarni, MD, Ph.D.
|
|
|
|
|
Final Results from a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab (CaboNivo) Alone or with Ipilimumab (CaboNivoIpi) for Metastatic Genitourinary Tumors
Presented By: Andrea B. Apolo, MD
|
|
|
|
|
Phase II/III Clinical Results of IL-15RαFc Superagonist N-803 with BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma in Situ (CIS) Patients
Presented By: Karim Chamie, MD
|
|
|
|
|
|
|
|
|
| Poster Highlights Session: Renal Cell Cancer - Gene Signatures
|
|
|
|
|
Angiogenic and T-Effector Subgroups Identified by Gene Expression Profiling (GEP) and Propensity for PBRM1 and BAP1 Alterations in Clear Cell Renal Cell Carcinoma (ccRCC)
Presented By: Pedro C. Barata, MD, MSc
|
|
|
|
|
Nivolumab + Cabozantinib (NIVO+CABO) Versus Sunitinib (SUN) for Advanced Renal Cell Carcinoma (aRCC): Outcomes by Sarcomatoid Histology and Updated Trial Results with Extended Follow-up of CheckMate 9ER
Presented By: Robert J. Motzer, MD
|
|
|
|
|
Outcomes for Patients in the Pembrolizumab+axitinib Arm with Advanced Renal Cell Carcinoma (RCC) Who Completed Two Years of Treatment in the Phase III KEYNOTE-426 Study
Presented By: Elizabeth R. Plimack, MD, MS
|
|
|
|
|
|
|
| Oral Abstract Session: Renal Cell Cancer
|
| Chair(s):Christian K. Kollmannsberger, MD and Nicole E Curci, MD
|
|
|
|
|
Phase 3 Trial of Lenvatinib (LEN) plus Pembrolizumab (PEMBRO) or Everolimus (EVE) Versus Sunitinib (SUN) Monotherapy as a First-Line Treatment for Patients (Pts) with Advanced Renal Cell Carcinoma (RCC) (CLEAR Study)
Presented By: Robert J. Motzer, MD
|
|
|
|
|
Phase 2 Study of the Oral Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Presented By: Toni K. Choueiri, MD
|
|
|
|
|
|
|
| Rapid Abstract Session: Renal Cell Cancer
|
| Chair(s):Stephen A. Boorjian, MD and Elizabeth Marie Wulff-Burchfield, MD
|
|
|
|
|
TIVO-3: Tivozanib in Patients with Advanced Renal Cell Carcinoma (aRCC) Who Have Progressed After Treatment with Axitinib
Presented By: Brian I. Rini, MD
|
|
|
|
|
|
|
|
|
